Clinical Evaluation and Outcome in Heart Failure Patients Receiving Chemotherapy with Different Anti-Cancer Agents
ESC Heart Failure · 2025
DOI: 10.1002/ehf2.15204 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift ESC Heart Failure, 2025. Verfasst von Tomiko Sunaga und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hospital Pharmaceutics, School of Pharmacy, Showa University, Tokyo, Japan. Hauptthemen laut MEDLINE: Heart Failure, Antineoplastic Agents, Neoplasms, Registries. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science.
Themen: Herzinsuffizienz, Onkologische Pflege
Abstract (Originalsprache)
Background
The optimal strategy for modern chemotherapy should be based on a comprehensive approach for cancer patients with cardiovascular diseases. Therefore, cardio-oncology has received increasing attention owing to the cardiotoxic effects of anti-cancer therapies.
Objectives
We aimed to evaluate the clinical characteristics and outcomes of patients with heart failure (HF) who received chemotherapy compared with those of a matched cohort with HF who did not receive chemotherapy, using real-world HF data.
Methods
This study was based on the Diagnosis Procedure Combination (DPC) database of the Japanese Registry of All Cardiac and Vascular Diseases (JROAD). We identified 1 328 113 patients who were hospitalized for HF between April 2012 and March 2021. The propensity score (PS) was estimated using a logistic regression model, with chemotherapy as the dependent variable, and a clinically score-matched analysis of 11 532 patients with HF with or without chemotherapy. The primary endpoint was readmission.
Results
Colon, lung, breast and prostate cancers accounted for >60% of all cancer types. After PS matching, readmission was significantly more frequently observed in patients with chemotherapy than those without [odds ratio (OR), 1.26; 95% confidence interval (CI) 1.17–1.36, P < 0.01]. In particular, treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) (OR, 1.69; 95% CI 1.39–2.07), taxane (OR, 2.95; 95% CI 2.11–4.12), anthracyclines (OR, 1.86; 95% CI 1.19–2.90) and fluorouracil agents (OR, 1.65; 95% CI 1.18–2.30) caused a higher risk of readmission.
Conclusions
Medical providers need to monitor and follow-up patients with HF, depending on the characteristics of the anti-cancer agents and types of cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hospital Pharmaceutics, School of Pharmacy, Showa University, Tokyo, Japan.
- Division of Applied Pharmaceutical Education and Research, Hoshi University, Tokyo, Japan.
- Department of Pharmacy, Showa University Hospital, Tokyo, Japan.
- Division of Cardiology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan.
- Department of Pharmacy, Showa University Northern Yokohama Hospital, Yokohama, Japan.
- Division of Pharmacotherapeutics, Department of Clinical Pharmacy, School of Pharmacy, Showa University, Tokyo, Japan.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Sunaga, T., Okada, T., Iso, Y., Ebato, M., Toshida, T., Nawata, S., Suzuki, H., & Kogo, M. (2025). Clinical Evaluation and Outcome in Heart Failure Patients Receiving Chemotherapy with Different Anti-Cancer Agents. ESC Heart Failure. https://doi.org/10.1002/ehf2.15204
Vancouver
Sunaga T, Okada T, Iso Y, Ebato M, Toshida T, Nawata S, et al. Clinical Evaluation and Outcome in Heart Failure Patients Receiving Chemotherapy with Different Anti-Cancer Agents. ESC Heart Failure. 2025. doi:10.1002/ehf2.15204
BibTeX
@article{Sunaga2025,
author = {Sunaga, Tomiko and Okada, Takahiro and Iso, Yoshitaka and Ebato, Mio and Toshida, Tsutomu and Nawata, Shuichi and Suzuki, Hiroshi and Kogo, Mari},
title = {Clinical Evaluation and Outcome in Heart Failure Patients Receiving Chemotherapy with Different Anti-Cancer Agents},
journal = {ESC Heart Failure},
year = {2025},
doi = {10.1002/ehf2.15204}
}
EUVIMED